Loss of BRD4 induces cell senescence in HSC/HPCs by deregulating histone H3 clipping
- 31 August 2023
- journal article
- research article
- Published by Springer Nature in EMBO Reports
- Vol. 24 (10) , e57032
Abstract
Bromodomain-containing protein 4 (BRD4) is overexpressed and functionally implicated in various myeloid malignancies. However, the role of BRD4 in normal hematopoiesis remains largely unknown. Here, utilizing an inducible Brd4 knockout mouse model, we find that deletion of Brd4 (Brd4Δ/Δ ) in the hematopoietic system impairs hematopoietic stem cell (HSC) self-renewal and differentiation, which associates with cell cycle arrest and senescence. ATAC-seq analysis shows increased chromatin accessibility in Brd4Δ/Δ hematopoietic stem/progenitor cells (HSC/HPCs). Genome-wide mapping with cleavage under target and release using nuclease (CUT&RUN) assays demonstrate that increased global enrichment of H3K122ac and H3K4me3 in Brd4Δ/Δ HSC/HPCs is associated with the upregulation of senescence-specific genes. Interestingly, Brd4 deletion increases clipped H3 (cH3) which correlates with the upregulation of senescence-specific genes and results in a higher frequency of senescent HSC/HPCs. Re-expression of BRD4 reduces cH3 levels and rescues the senescence rate in Brd4Δ/Δ HSC/HPCs. This study unveils an important role of BRD4 in HSC/HPC function by preventing H3 clipping and suppressing senescence gene expression.Keywords
Funding Information
- Cancer Prevention and Research Institute of Texas (RP190077)
- Cancer Prevention and Research Institute of Texas (RP160732)
- Cancer Prevention and Research Institute of Texas (RP180349)
- National Cancer Institute (HL149318)
- National Cancer Institute (HL158081)
- National Cancer Institute (CA172408)
- National Cancer Institute (HL145883)
- National Cancer Institute (CA240139)
- National Cancer Institute (1R01CA251698‐01)
- Basic Research Laboratory (1S10OD021805‐01)
- HHS | NIH | NCI | Center for Biomedical Informatics and Information Technology, National Cancer Institute (NIH‐NCI P30 CA054174)
- Leukemia and Lymphoma Society (M1701632)
This publication has 44 references indexed in Scilit:
- Contribution of histone N‐terminal tails to the structure and stability of nucleosomesFEBS Open Bio, 2013
- Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemiaNature, 2011
- Targeting MYC dependence in cancer by inhibiting BET bromodomainsProceedings of the National Academy of Sciences of the United States of America, 2011
- BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-MycCell, 2011
- RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemiaNature, 2011
- Selective inhibition of BET bromodomainsNature, 2010
- Brd4 engagement from chromatin targeting to transcriptional regulation: selective contact with acetylated histone H3 and H4F1000 Biology Reports, 2009
- Cathepsin L Proteolytically Processes Histone H3 During Mouse Embryonic Stem Cell DifferentiationCell, 2008
- Recruitment of P-TEFb for Stimulation of Transcriptional Elongation by the Bromodomain Protein Brd4Molecular Cell, 2005
- The Bromodomain Protein Brd4 Is a Positive Regulatory Component of P-TEFb and Stimulates RNA Polymerase II-Dependent TranscriptionMolecular Cell, 2005